He felt like he was reborn with the cancer vaccine he tried as ‘Last Hope’ Adrian Taylor, is responding to treatment and one of his tumors has shrunk. Taylor was also one of the first people to benefit from cancer vaccines in England. there was hope.

To complement Adrian Taylor’s treatment process personalized cancer vaccines In this article you can also look back on the treatment process and perhaps open a new door for the treatment process by informing one of the cancer patients in your area.

Adrian Taylor had only one hope. And that was to participate in a new clinical trial.

Adrian Taylor in 2021 head and neck cancer captured. After receiving chemotherapy and radiotherapy, he had a PET/CT scan in 2022. Although the good news was that the cancer in his neck and head was gone, the cancer spread to his right lung and the 9mm tumor was removed. incurable He discovered he was qualified.

When he learned there was a 100% chance of dying without treatment, Taylor met with his doctor, figuring he had to survive for his four children and wife. Taylor realized that one of the tumors had grown from 9mm to 25mm in a short time and was not suitable for surgery. experimental treatments He started doing research.

Personalized cancer vaccine Taylor, who signed up and was deemed suitable for an experimental treatment, was given a new dose every three weeks after receiving his first dose and was scanned every eight weeks. The results of the latest scan were promising for both the doctor and Taylor. Taylor’s largest tumor, which was 25 mm, shrank to 4.6 mm.

Taylor also stated in her interviews that she was very happy with the moments where she was able to do many things that she thought she could not do. Taylor, treatment limited to two years He will continue to receive the vaccine regularly during the trial.

What is a personalized cancer vaccine?

The one that will revolutionize cancer mRNA, the same approach used for COVID-19 vaccines. mRNA has actually been around for almost 10 years. cancer treatment Tested on. Its success in COVID-19 was promising for scientists.

mRNA is a protein that instructs cells to make proteins. genetic planning. First of all, the proteins that cause tumor growth genetic mutations is analyzed. A molecule, also called a neoantigen, is then produced that provides instructions for tumor proteins to the cells.

After the produced molecules are injected into the patient, the patient is instructed to produce proteins that will trigger an immune response against the proteins present in the tumor cells. Dendritic cells, which are immune cells that can be called sentinels of the immune system, translate the incoming vaccine and release the antigens into the cells. initiates an immune response.

Studies continue based on cancer types.

Many clinical trials colorectal and pancreatic cancer continues to test its mRNA vaccine against several types of cancer. These vaccines are not being evaluated alone, but in combination with other immune-boosting drugs.

Prostate and skin cancer Six cancer vaccines are being tested in Clatterbridge alone Experts say personalized vaccines should be created for 10,000 patients by 2030.

mRNA is more than a vaccine.

James Spicer, professor of experimental cancer medicine at King’s College London, emphasizes that it is not enough to simply call mRNA a vaccine. Spicer for mRNA “RNA therapies” say.

It seems possible that metastatic cells may remain after the tumor is removed from patients who have undergone surgery for cancer. Instead of waiting for the tumor to spread, the tumor’s genetic code is sequenced and a vaccine against abnormal proteins is prepared. So if the immune system recognizes this protein and encounters it again, learn to fight.

Promising results continue to be achieved.

Other results from personalized cancer vaccine trials are promising for the future of cancer. vaccinated high risk skin cancer Tests on more than three-quarters of patients showed no relapse after 18 months.

One of the most aggressive forms of cancer to pancreatic cancer Good news was also reported in studies on this topic. Half of the 16 pancreatic cancer patients who participated in the vaccine trial at Memorial Sloan Kettering Cancer Center in New York there was no relapse or this process has been delayed.

We hope that the vaccine studies will continue at full speed and become accessible to everyone.